

Deep TMS for the Aging Population

Adam Shames, Director of Business Development & Strategy, Brainsway

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**

- Brainsway is a publically traded company with revenue growth of the past 12 months, focusing its sales on the USA MDD market and gradually increasing its presence in ROW. Business models include direct sales, lease and Pay per Use models.
- Brainsway is proud to have a world-class expert advisory board and is led by Mr. Michlin, a highly experienced executive in the biomed commercialization market.

- **Business Strategy**

- Brainsway sells to the US MDD market via its wholly-owned US subsidiary, and in other regions via exclusive distributors and local agents.
- Brainsway's technology is in use in numerous hospitals, private clinics and institutes worldwide, with over 20,000 patients treated to date.

- **Core Technology**

- Brainsway's Deep Transcranial Magnetic Stimulation (Deep TMS) revolutionizes the treatment of brain disorders by providing a non-invasive therapy that allows patients with Major Depressive Disorder (MDD) and other brain disorders to regain wellbeing, calm and happiness within just a few weeks. Our proprietary platform, covered by 7 family patents, is capable of treating a broad range of brain disorders, by optimizing the shape and characteristics of the magnetic coils, resulting in a deep and robust stimulatory electric field in the brain.

- **Product Profile/Pipeline**

- Brainsway has been cleared by the FDA for treating major depressive disorder, and four multi-center trials underway, with the goal of obtaining clearance for treating bipolar depression, obsessive-compulsive disorder, PTSD, and smoking addiction. We are also conducting clinical feasibility trials for treatment of Alzheimer's disease, Parkinson's disease, stroke, epilepsy and chronic pain.
- Our treatment is non-invasive and has no systemic side effects.

- **What's Next?**

- Brainsway is heavily investing in novel brain stimulation and completing technologies methods, aiming to expand its clinical offering as well as to increase effectiveness, precision and comfort for its existing solutions.
- We have strong clinical backing, having participated in over 60 studies worldwide, resulting in more than 50 scientific publications and many collaborations.